F15063, a potential antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 375, Issue 4, 2007, Pages 241-250

  Assié, Marie Bernadette ^a   Bardin, Laurent ^a   Auclair, Agnès ^a   Consul Denjean, Nathalie ^a   Sautel, François ^a   Depoortère, Ronan ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antipsychotic; Apomorphine induced climbing and sniffing; D2 like receptor occupancy; F15063; Mouse brain; Plasma levels

Indexed keywords

[N 9(2,2 DIMETHYL 2,3 DIHYDRO BENZOFURAN 7 YLOXY)ETHYL) 3 (CYCLOPENT 1 ENYL)] BENZYLAMINE FUMARATE; BENZYLAMINE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; F15063; HALOPERIDOL; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CLIMBING; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OLFACTORY BULB; SNIFFING;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZAMIDES; BENZOFURANS; BENZYLAMINES; CYCLOPENTANES; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; MICE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; SEROTONIN AGONISTS;

EID: 34247884365     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0162-x     Document Type: Article

References (35)

1. Abi-Dargham A, Laruelle M (2005) Mechanisms of action of second generation antipsychotic drugs in schizophrenia: insights from brain imaging studies. Eur Psychiatry 20:15-27
2. Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
3. 4 partial agonist properties: III) Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents. Eur Neuropsychopharmacol 16(Suppl 4):S432
4. 2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol 373:441-450
5. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46
6. 1A agonist properties. Neuropsychopharmacology 31:1869-1879
7. 123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 160:1413-1420
8. 1A receptor activities. J Med Chem 50:865-876
9. 4 partial agonist properties: (III) Profile in tests predictive of activity against cognitive deficits and negative symptoms of schizophrenia. Br J Pharmacol. DOI 10.1038/sj.bjp.0707160
10. 4 partial agonist properties: (II) Profile in tests predictive of activity against positive symptoms of schizophrenia. Br J Pharmacol. DOI 10.1038/sj.bjp.0707159
11. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine- relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
12. 2 receptor occupancy in rats. Neuropsychopharmacology 30(Suppl 1s):S256
13. Hirose G (2006) Drug induced parkinsonism: a review. J Neurol 253 (Suppl 3):III/22-III/24
14. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharm Biol Psychiatry 27:1081-1090
15. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50:873-883
16. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
17. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003) Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631
18. Lee BH, Kim YK (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharm Biol Psychiatry 30:658-662
19. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003) New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581-1589
20. Maguire GA (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63(Suppl 4):56-62
21. Medori R, Mannaert E, Grunder G (2006) Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 16:233-240
22. 1A receptors. J Pharmacol Exp Ther 295:853-861
23. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760
24. 4 partial agonist properties: (I) in vitro, receptor affinity and efficacy profile. Br J Pharmacol. DOI 10.1038/sj.bjp.0707158
25. Olsen CK, Brennum LT, Kreilgaard M (2006) Pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Society for Neuroscience, Atlanta, GA, 2006 Online 93.15
26. Protais P, Costentin J, Schwartz JC (1976) Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50:1-6
27. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
28. 1A receptor system: possible implications for schizophrenic negative symptomatology. Psychiatr Ann 26:88-92
29. 123I]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177:408-415
30. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y (2004) Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 7:19-26
31. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S (2002) Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 7:317-321
32. Tort ABL, Souza DO, Lara DR (2006) Theoretical insights into the mechanism of action of atypical antipsychotics. Prog Neuropsychopharm Biol Psychiatry 30:541-548
33. Vacher B, Cuisiat S, Koek W, Colpaert FC (2002) 3-(Cyclopenten-1-yl)- benzyl-or 3-(Cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia. Patent no WO 2004/035561 A1. Priority 16 October 2002
34. Wolf W (2003) DU-127090. Curr Opin Investig Drugs 4:72-76
35. Zetler G, Baumann GH (1985) Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31:318-327